Original Article

You have free access to this content

Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel†‡

An Analysis of Gynecologic Oncology Group Trials

  1. John H. Farley MD1,¶,*,
  2. Chunqiao Tian MD2,
  3. G. Scott Rose MD3,
  4. Carol L. Brown MD4,
  5. Michael Birrer MD, PhD5,§,
  6. G. Larry Maxwell MD3

Article first published online: 17 JUN 2009

DOI: 10.1002/cncr.24482

Issue

Cancer

Cancer

Volume 115, Issue 18, pages 4210–4217, 15 September 2009

Additional Information

How to Cite

Farley, J. H., Tian, C., Rose, G. S., Brown, C. L., Birrer, M. and Larry Maxwell, G. (2009), Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel. Cancer, 115: 4210–4217. doi: 10.1002/cncr.24482

Author Information

  1. 1

    Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Maryland

  2. 2

    Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York

  3. 3

    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and the United States Military Cancer Institute, Walter Reed Army Medical Center, Washington, DC

  4. 4

    Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York

  5. 5

    Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

  1. §

    Dr. Michael Birrer's current address is Massachusetts General Hospital, Boston, Massachusetts

  1. Fax: (301)295-0814

*Uniformed Serviced University of Health Sciences, Department of Obstetrics and Gynecology, 4301 Jones Bridge Road, Bethesda, MD 20832

  1. †

    The following Gynecologic Oncology Group member institutions participated in this study: University of Alabama at Birmingham; Duke University Medical Center; Abington Memorial Hospital; University of Rochester Medical Center; Walter Reed Army Medical Center; Wayne State University; University of Minnesota Medical School; Emory University Clinic; University of Mississippi Medical Center; Colorado Gynecologic Oncology Group, P.C.; University of California at Los Angeles; University of Washington; University of Pennsylvania Cancer Center; Milton S. Hershey Medical Center; Georgetown University Hospital; University of Cincinnati; University of North Carolina School of Medicine; University of Texas Southwestern Medical Center at Dallas; Indiana University School of Medicine; Wake Forest University School of Medicine; Albany Medical College; University of California Medical Center at Irvine; Tufts-New England Medical Center; Rush-Presbyterian–St. Luke's Medical Center; State University of New York Downstate Medical Center; University of Kentucky; Community Clinical Oncology Program, the Cleveland Clinic Foundation; Johns Hopkins Oncology Center; State University of New York at Stony Brook; Eastern Pennsylvania GYN/ONC Center, P.C.; Washington University School of Medicine; Cooper Hospital/University Medical Center; Columbus Cancer Council; University of Massachusetts Medical School; Fox Chase Cancer Center; Medical University of South Carolina; Women's Cancer Center, University of Oklahoma; University of Virginia Health Sciences Center; University of Chicago; Tacoma General Hospital, Thomas Jefferson University Hospital; Case Western Reserve University; Tampa Bay Cancer Consortium; North Shore University Hospital; Gynecologic Oncology Network; Oregon Health Sciences University; University of Southern California at Los Angeles; University of Miami School of Medicine; Stanford University Medical Center; Eastern Virginia Medical School; University of Arizona Health Science Center; Mayo Clinic; and Long Island Jewish Medical Center.

  2. ‡

    This article is US Government work and, as such, is in the public domain in the United States of America.

Publication History

  1. Issue published online: 4 SEP 2009
  2. Article first published online: 17 JUN 2009
  3. Manuscript Accepted: 5 FEB 2009
  4. Manuscript Revised: 28 JAN 2009
  5. Manuscript Received: 10 DEC 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (199K)

References

  • 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
    Direct Link:
  • 2
    Goodman MT, Howe HL, Tung KH, et al. Incidence of ovarian cancer by race and ethnicity in the United States, 1992-1997. Cancer. 2003; 97: 2676-2685.
    Direct Link:
  • 3
    Farley J, Risinger JI, Rose GS, Maxwell GL. Racial disparities in blacks with gynecologic cancers. Cancer. 2007; 110: 234-243.
    Direct Link:
  • 4
    Howe HL, Tung KH, Coughlin S, Jean-Baptiste R, Hotes J. Race/ethnic variations in ovarian cancer mortality in the United States, 1992-1997. Cancer. 2003; 97: 2686-2693.
    Direct Link:
  • 5
    Chan JK, Zhang M, Hu JM, Shin JY, Osann K, Kapp DS. Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States. J Surg Oncol. 2008; 97: 103-107.
    Direct Link:
  • 6
    Cress RD, O'Malley CD, Leiserowitz GS, Campleman SL. Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol. 2003; 21: 1530-1535.
  • 7
    Parham G, Phillips JL, Hicks ML, et al. The National Cancer Data Base report on malignant epithelial ovarian carcinoma in African-American women. Cancer. 1997; 80: 816-826.
    Direct Link:
  • 8
    Brun JL, Feyler A, Chene G, Saurel J, Brun G, Hocke C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol. 2000; 78: 21-27.
  • 9
    McGuire V, Jesser CA, Whittemore AS. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol. 2002; 84: 399-403.
  • 10
    O'Malley CD, Cress RD, Campleman SL, Leiserowitz GS. Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol. 2003; 91: 608-615.
  • 11
    Barnholtz-Sloan JS, Tainsky MA, Abrams J, et al. Ethnic differences in survival among women with ovarian carcinoma. Cancer. 2002; 94: 1886-1893.
    Direct Link:
  • 12
    Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001; 19: 1001-1007.
  • 13
    Winter WE3rd, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007; 25: 3621-3627.
  • 14
    Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354: 34-43.
  • 15
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334: 1-6.
  • 16
    Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2000; 18: 106-115.
  • 17
    Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21: 3194-3200.
  • 18
    Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004; 351: 2489-2497.
  • 19
    Spriggs DR, Brady MF, Vaccarello L, et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007; 25: 4466-4471.
  • 20
    Hoskins WJ, Rubin SC. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol. 1991; 18: 213-221.
  • 21
    Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol. 2008; 108: 276-281.
  • 22
    McGuire V, Herrinton L, Whittemore AS. Race, epithelial ovarian cancer survival, and membership in a large health maintenance organization. Epidemiology. 2002; 13: 231-234.
  • 23
    Johnson JA. Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci. 1997; 86: 1328-1333.
    Direct Link:
  • 24
    Tam KF, Chan YM, Ng TY, Wong LC, Ngan HY. Ethnicity is a factor to be considered before dose planning in ovarian cancer patients to be treated with topotecan. Int J Gynecol Cancer. 2006; 16: 135-139.
    Direct Link:
  • 25
    McCollum AD, Catalano PJ, Haller DG, et al. Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002; 94: 1160-1167.
View Full Article (HTML) Get PDF (199K)